Kenneth Andrade, Head Investment at, IDFC Mutual Fund told CNBC-TV18, "There is a very large opportunity which is there in pharmaceuticals and most companies are present in that opportunity. While currency is in favour it is not the only USP that these companies have. They have built their presence in the environment outside."
"All said and done they also come at fairly expensive valuations at this point in time. So from a portfolio standpoint we are fairly neutral on pharma sector. We have a handful of companies that are participating in most portfolios."
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
